Charles River Laboratories (CRL) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY25 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $338.26 -3.87%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.12, $0.62 better than the analyst estimate of $2.50. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $984.86 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $9.90-$10.10, versus the consensus of $9.65.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- Alphabet stock jumps as buyers return after selloff
- McDonald's shares gain as profit tops expectations despite revenue miss
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
